Category Archives: Topics

Roche Positive Ph1 Oral GLP-1RA Obesity Results

Roche announced positive topline results for CT-996 (QD oral GLP-1RA) from its ongoing Ph1 trial in participants with and without T2DM (view CT.gov record). According to the press release, treatment with CT-996 resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks (p <0.001). Following the news, Roche’s stock increased ~7.5%. Below, FENIX provides highlights and brief thoughts on the potential CT-996 differentiation.

This content is for Read Less members only.
Already a member? Log in here

Ozempic Associated with Decreased Risk of Dementia Among Other Outcomes

Findings from a University of Oxford study published in the Lancet demonstrated Ozempic decreased the risk of developing dementia by 48% vs. sitagliptin after one year and protected against other cognitive problems (view article; view study). For context, the study evaluated 12-month neurological and psychiatric outcomes of semaglutide vs. sitagliptin, empagliflozin, and glipizide using electronic health records. Below, FENIX provides highlights and insights into the study’s findings.

This content is for Read Less members only.
Already a member? Log in here

Novo Nordisk’s QW Insulin Icodec Receives CRL

Novo Nordisk announced FDA issued a CRL regarding the QW insulin icodec BLA for the treatment of diabetes. According to the press release, the CRL outlines requests related to the manufacturing process and the T1DM indication. Novo stated it is evaluating the content of the CRL and will work closely with FDA to fulfill the requests. Of note, Novo does not expect to be able to fulfill the requests during 2024. Below, FENIX provides brief thoughts on the CRL in the context of the recent negative FDA adcom vote.

This content is for Read Less members only.
Already a member? Log in here

BI Announces Triple Agonist for Obesity Treatment; Merck Initiates Ph2a Trial of Efinopegdutide in MASLD

Two cardiometabolic-related news items have been observed: Boehringer Ingelheim and Gubra announced the launch of a Ph1 trial evaluating its triple agonist, BI 3034701, in obesity (view press release); and Merck initiated a Ph2a trial evaluating Q2W vs. QW administration of efinopegdutide (MK-6024) in MASLD (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items, including thoughts on potential MOAs for BI’s triple agonist.

This content is for Read Less members only.
Already a member? Log in here

Novo’s Ocedurenone CLARION-CKD Trial Fails; NeuroBo Doses First Patient in MAD Ph1 Obesity Trial; Another Generic Liraglutide FDA Approval

Three cardiometabolic-related news items have been observed: Novo Nordisk announced its CLARION-CKD Ph3 trial evaluating ocedurenone (nsMRA) failed to meet its primary endpoint (view CT.gov record; view press release); NeuroBo Pharmaceuticals announced it dosed first patients in the Part 2 MAD portion of its Ph1 trial of DA-1726 for obesity (view CT.gov record; view press release); and Hanyu Pharmaceuticals (and Hikma) announced its liraglutide ANDA has been granted tentative approval (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here